Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Partners With Integumen To Detect Covid-19 In Waste Water

Mon, 13th Jul 2020 11:23

(Alliance News) - Avacta PLC on Monday announced that it has entered into a collaboration with Integumen PLC to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of Covid-19 in waste water.

Affimer reagents, a technology developed by drug and diagnostic tool developer Avacta, are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations.

A reagent is a substance used, in this case for detection, for chemical analysis or other reactions.

Testing of the Affimer reagents will take place over the next few weeks after which validation of the sensors will be carried out using real SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen.

If these tests go well, it will enable the identification of Covid-19 hotspots in waste-water supplies as the virus can be found in the waste of most Covid-19 patients.

This can provide an early warning system in which authorities can be alerted through Integumen's alert system to prevent the spread of the disease to the wider community.

Avacta Chief Executive Alastair Smith said: "With the spread of Covid-19 continuing to accelerate globally, we are proud to work with partners like Integumen to provide our Affimer reagents for development on a range of platforms to combat the pandemic.

"This collaboration has the potential to deliver a product that will play a crucial role in the early detection of COVID-19 hotspots around the world."

Integumen is a scientific research and AI-as-a-service company focused on production and analysis of bacteria, virus and toxins.

Integumen and Avacta intend to enter a supply agreement for the supply of Affimers into Integumen's sensors upon the successful completion of the tests.

Avacta shares were down 0.2% at 119.25 pence each on Monday morning in London. Integumen shares were up 5.3% at 2.00p each.

Integumen's sensors will then be retrofitted into London-based water supply company Modern Water PLC's Microtox water contamination system units to detect Covid-19 in the water supply.

Modern Water Chief Executive Simon Humphrey said: "We are delighted to be in a position to have a distribution channel that can make the most of the roll-out of the real-time novel sensors for the detection of SARS-CoV-2.

"The completion of this evaluation which, if successful, could identify the level of infection in a community without the need for testing individuals is a very exciting breakthrough and we look forward to working with Integumen to make it happen."

Modern Water shares were up 11% at 2.04p each on Monday morning in London.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 Jul 2021 11:30

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Read more
14 Jul 2021 11:10

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

Read more
14 Jul 2021 09:02

Avacta gets ISO certification for Affirmer manufacture and distribution

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced on Wednesday that its life sciences diagnostics division has achieved ISO 13485 certification on the quality management system for the manufacture and distribution of 'Affimer' reagents, for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

Read more
29 Jun 2021 12:12

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

Read more
29 Jun 2021 11:37

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

Read more
29 Jun 2021 08:36

Avacta rapid Covid-19 test detects Delta variant in study

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.

Read more
23 Jun 2021 10:28

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

Read more
21 Jun 2021 19:24

IN BRIEF: Avacta signs distribution deal for its Covid test

IN BRIEF: Avacta signs distribution deal for its Covid test

Read more
21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
21 Jun 2021 08:37

Avacta enters non-exclusive distribution deal for Covid-19 test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).

Read more
11 Jun 2021 12:27

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

Read more
11 Jun 2021 11:40

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

Read more
7 Jun 2021 11:31

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

Read more
7 Jun 2021 10:11

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

Read more
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.